A First-in-Human, Phase 1/2 Study of LAT010 in Patients with Advanced Solid Tumors (LIGHTSPEED-1)
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Latticon Antibody Therapeutics, Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06277219
- Locations
- 🇺🇸
D&H Cancer Research Center, Margate, Florida, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath